Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.65 |
| ▸ | PDE4A | P27815 | 17/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205486 | 0.92 | PDE4B (0.64) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL19244904 | 0.91 | PDE4B (0.65) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL19205479 | 0.91 | PDE4B (0.65) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL19205483 | 0.90 | PDE4B (0.65) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL19205478 | 0.89 | PDE4B (0.63) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL19205487 | 0.88 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL19205482 | 0.88 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL19205480 | 0.88 | PDE4B (0.61) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL21657639 | 0.87 | PDE4D (0.60) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL11928974 | 0.87 | PDE4B (0.67) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210974-B1 | PRODRUG OF ROFLUMILAST | HISAMITSU PHARMACEUTICAL CO (JP) | 2020-01-29 | — | — | EP | disclosed |
| EP-3210974-B1 | PRODRUG OF ROFLUMILAST | HISAMITSU PHARMACEUTICAL CO (JP) | 2020-01-29 | — | — | EP | disclosed |
| US-9969688-B2 | Roflumilast prodrugs | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9969688-B2 | Roflumilast prodrugs | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9969688-B2 | Roflumilast prodrugs | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2018-05-15 | — | — | US | disclosed |
| EP-3210974-A1 | PRODRUG | Hisamitsu Pharmaceutical Co., Inc. (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170233343-A1 | PRODRUG | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233343-A1 | PRODRUG | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233343-A1 | PRODRUG | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233343-A1 | PRODRUG | CYP2B6, CYP2D6, CYP2A6 | PDE4B 684/4885PDE4D 1028/4885PDE4A 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.